Towards the development of human immune-system-on-a-chip platforms
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Organ-on-a-chip (OoCs) platforms could revolutionize drug discovery and might ultimately become essential tools for precision therapy. Although many single-organ and interconnected systems have been described, the immune system has been comparatively neglected, despite its pervasive role in the body and the trend towards newer therapeutic products (i.e., complex biologics, nanoparticles, immune checkpoint inhibitors, and engineered T cells) that often cause, or are based on, immune reactions. In this review, we recapitulate some distinctive features of the immune system before reviewing microfluidic devices that mimic lymphoid organs or other organs and/or tissues with an integrated immune system component.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207 · cited 1×
“Third, selective activation or blockade of the immune system has emerged as a powerful therapeutic approach in its own right: significant results in at least some types of cancer have been reported for the use of immune checkpoint inhibitors [12], bispecific antibodies [13], and engineered T cells [14].”
BackgroundNorelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406 · cited 1×
“The causes and remedies of these unintended reactions remain incompletely understood and represent an active area of investigation [16,17].”
BackgroundCAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272 · cited 1×
“The causes and remedies of these unintended reactions remain incompletely understood and represent an active area of investigation [16,17].”
BackgroundOrgans-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185
Kim, H. J., Li, H., Collins, J. J., & Ingber, D. E. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522193112 · Cited by 922
Zhang, Y. S., Aleman, J., Shin, S. R., Kilic, T., Kim, D., Mousavi Shaegh, S. A., Massa, S., Riahi, R., Chae, S., Hu, N., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612906114 · Cited by 833
Self-citationMeasures of degeneracy and redundancy in biological networks
Tononi, G., Sporns, O., & Edelman, G. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3257 · Cited by 632
Engineering microscale cellular niches for three-dimensional multicellular co-cultures
Huang, C. P., Lu, J., Seon, H., Lee, A. P., Flanagan, L. A., Kim, H.-Y., Putnam, A. J., & Jeon, N. L. (2009) · Lab on a Chip · doi:10.1039/b818401a · Cited by 384
Benam, K. H., Novak, R., Nawroth, J., Hirano-Kobayashi, M., Ferrante, T. C., Choe, Y., Prantil-Baun, R., Weaver, J. C., Bahinski, A., Parker, K. K., et al. (2016) · Cell Systems · doi:10.1016/j.cels.2016.10.003 · Cited by 309
Cited by
A guide to the organ-on-a-chip
Leung, C. M., de Haan, P., Ronaldson-Bouchard, K., Kim, G.-A., Ko, J., Rho, H. S., Chen, Z., Habibovic, P., Jeon, N. L., Takayama, S., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00118-6 · Cited by 1,116
Organ-on-a-Chip: A New Paradigm for Drug Development
Ma, C., Peng, Y., Li, H., & Chen, W. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.009 · Cited by 576
DNA Vaccines—How Far From Clinical Use?
Hobernik, D., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113605 · Cited by 457
Immune Organs and Immune Cells on a Chip: An Overview of Biomedical Applications
Morsink, M., Willemen, N., Leijten, J., Bansal, R., & Shin, S. (2020) · Micromachines · doi:10.3390/mi11090849 · Cited by 73
“Due to i s relevance for major diseases and the development of target d therapeutic strategies using antibodies and the immune system, the evaluation of the imm ne system using 3D culture systems such as organ-on-a-chip (OoC) models has steadily gained momentum, as can be seen in Figure 1B [19,20].”
Background3D Immunocompetent Organ‐on‐a‐Chip Models
Maharjan, S., Cecen, B., & Zhang, Y. S. (2020) · Small Methods · doi:10.1002/smtd.202000235 · Cited by 62
Self-citationFactors to consider when interrogating 3D culture models with plate readers or automated microscopes
Riss, T., & Trask, O. J. (2021) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-020-00537-3 · Cited by 26
“model an inflammatory response by lymphocyte activation and chemotaxis (Polini et al. 2019) are further examples of”
Background
Metadata
- Authors
- Polini, A., del Mercato, L. L., Barra, A., Zhang, Y. S., Calabi, F., & Gigli, G.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 24
- Issue
- 2
- Pages
- 517-525
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2898024988
- Cited by
- 99
- References
- 20
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.